INT191931

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.29
First Reported 2006
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 13
Total Number 14
Disease Relevance 4.83
Pain Relevance 0.68

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

transport (Gopc) Golgi apparatus (Gopc) plasma membrane (Gopc)
cytoplasm (Gopc)
Anatomy Link Frequency
pericyte 4
body 2
Gopc (Mus musculus)
Pain Link Frequency Relevance Heat
Inflammation 62 100.00 Very High Very High Very High
noradrenaline 14 94.16 High High
Eae 39 91.04 High High
Arthritis 8 78.68 Quite High
Paracetamol 10 66.12 Quite High
Catecholamine 12 56.12 Quite High
cytokine 46 55.80 Quite High
chemokine 57 50.00 Quite Low
imagery 48 50.00 Quite Low
Pain 6 33.68 Quite Low
Disease Link Frequency Relevance Heat
INFLAMMATION 104 100.00 Very High Very High Very High
Obesity 85 99.48 Very High Very High Very High
Stress 110 92.88 High High
Targeted Disruption 146 91.68 High High
Cancer 197 89.64 High High
Apoptosis 19 88.96 High High
Anxiety Disorder 62 88.56 High High
Hyperplasia 3 87.12 High High
Carcinoma 22 85.52 High High
Adhesions 3 82.64 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Pre-treatment of an adjacent tissue section with 1 mM lactose resulted in a complete inhibition of specific binding of [18F]FEDL to pancreatic tissue (Fig. 4C).
Negative_regulation (inhibition) of Fig Binding (binding) of
1) Confidence 0.29 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2776527 Disease Relevance 0.21 Pain Relevance 0
0.2789; Fig. 4H; with delays: genotype effect, F1,38?
Negative_regulation (effect) of Fig Binding (0.2789) of
2) Confidence 0.27 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2830479 Disease Relevance 0.54 Pain Relevance 0.05
m caudal relative to the sections evaluated for Mac-1 immunoreactivity (Fig. 3 or Fig. 4) and 30 ?
Negative_regulation (evaluated) of Fig Binding (immunoreactivity) of
3) Confidence 0.24 Published 2006 Journal J Neuroinflammation Section Body Doc Link PMC1440849 Disease Relevance 0.48 Pain Relevance 0
m caudal relative to the sections evaluated for Mac-1 immunoreactivity (Fig. 3 or Fig. 4) and 30 ?
Negative_regulation (evaluated) of Fig Binding (immunoreactivity) of
4) Confidence 0.24 Published 2006 Journal J Neuroinflammation Section Body Doc Link PMC1440849 Disease Relevance 0.48 Pain Relevance 0
0.5, Fig. 1A) but was not related to apoA1 or body mass index (both r?
Neg (not) Negative_regulation (related) of Fig Binding (0.5) of in body associated with obesity
5) Confidence 0.16 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2582480 Disease Relevance 1.00 Pain Relevance 0.15
S1) and decreased pericyte coverage (Fig. 3, Fig.
Negative_regulation (decreased) of Fig Binding (coverage) of in pericyte
6) Confidence 0.12 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2781164 Disease Relevance 0.40 Pain Relevance 0
S1) and decreased pericyte coverage (Fig. 3, Fig.
Negative_regulation (decreased) of Fig Binding (coverage) of in pericyte
7) Confidence 0.12 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2781164 Disease Relevance 0.40 Pain Relevance 0
Moreover, Evasin-3 treatment significantly reduced the inflammatory hypernociception associated with this model (Fig. 9 c), and interestingly, the treatment resulted in decreased local production of TNF-?
Negative_regulation (reduced) of Fig Binding (associated) of associated with inflammation
8) Confidence 0.10 Published 2008 Journal The Journal of Experimental Medicine Section Body Doc Link PMC2526197 Disease Relevance 0.61 Pain Relevance 0.17
B DNA binding decreased with increasing concentrations of NAPQI (Fig. 1C) and DNCB (Fig. 1D).
Negative_regulation (decreased) of Fig Binding (binding) of
9) Confidence 0.09 Published 2010 Journal Biochemical Pharmacology Section Body Doc Link PMC2884179 Disease Relevance 0.13 Pain Relevance 0.13
B DNA binding decreased with increasing concentrations of NAPQI (Fig. 1C) and DNCB (Fig. 1D).
Negative_regulation (decreased) of Fig Binding (binding) of
10) Confidence 0.09 Published 2010 Journal Biochemical Pharmacology Section Body Doc Link PMC2884179 Disease Relevance 0.13 Pain Relevance 0.13
ETGE, Fig. 4A, lanes 5 and 8) defective for KEAP1 binding (Fig. 4A, lanes 6 and 9).
Negative_regulation (defective) of Fig Binding (binding) of
11) Confidence 0.09 Published 2010 Journal The Journal of Biological Chemistry Section Body Doc Link PMC2898415 Disease Relevance 0 Pain Relevance 0
ETGE, Fig. 4A, lanes 5 and 8) defective for KEAP1 binding (Fig. 4A, lanes 6 and 9).
Negative_regulation (defective) of Fig Binding (binding) of
12) Confidence 0.09 Published 2010 Journal The Journal of Biological Chemistry Section Body Doc Link PMC2898415 Disease Relevance 0 Pain Relevance 0
-mediated suppression of Sp1/Sp3 binding (Fig. 7C).
Negative_regulation (suppression) of Fig Binding (binding) of
13) Confidence 0.08 Published 2008 Journal Cell Signal Section Body Doc Link PMC2586094 Disease Relevance 0 Pain Relevance 0.03
B DNA binding (Supplemental Fig. 4B), two key transcriptional activators of iNOS.
Negative_regulation (activators) of Fig Binding (binding) of
14) Confidence 0.05 Published 2008 Journal Current Chemical Genomics Section Body Doc Link PMC2803434 Disease Relevance 0.46 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox